At the time of writing, Nuvation Bio Inc [NUVB] stock is trading at $2.45, up 4.70%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NUVB shares have gain 9.38% over the last week, with a monthly amount drifted -0.41%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nuvation Bio Inc [NYSE: NUVB] stock has seen the most recent analyst activity on April 23, 2025, when Citizens JMP initiated its Mkt Outperform rating and assigned the stock a price target of $6. Previously, Jefferies upgraded its rating to Buy on March 27, 2024, and elevated its price target to $10. On March 26, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $5 on the stock. Jefferies downgraded its rating to a Hold and decreased its price target to $2 on January 06, 2023. BTIG Research downgraded its rating to a Neutral. BMO Capital Markets downgraded its rating to Market Perform for this stock on August 02, 2022, and downed its price target to $2.50. In a note dated May 04, 2022, H.C. Wainwright initiated an Buy rating and provided a target price of $14 on this stock.
For the past year, the stock price of Nuvation Bio Inc fluctuated between $1.54 and $3.97. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Nuvation Bio Inc [NYSE: NUVB] shares were valued at $2.45 at the most recent close of the market. An investor can expect a potential return of 144.9% based on the average NUVB price forecast.
Analyzing the NUVB fundamentals
Gross Profit Margin for this corporation currently stands at 0.14% with Operating Profit Margin at -18.83%, Pretax Profit Margin comes in at -55.34%, and Net Profit Margin reading is -55.34%. To continue investigating profitability, this company’s Return on Assets is posted at -1.23, Equity is -1.48 and Total Capital is -0.47. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.33 points at the first support level, and at 2.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.51, and for the 2nd resistance point, it is at 2.58.
Ratios To Look Out For
It is important to note that Nuvation Bio Inc [NYSE:NUVB] has a current ratio of 9.01. As well, the Quick Ratio is 9.01, while the Cash Ratio is 0.91. Considering the valuation of this stock, the price to sales ratio is 76.06, the price to book ratio is 1.98.
Transactions by insiders
Recent insider trading involved Liu Dongfang, CHIEF MEDICAL OFFICER, that happened on May 02 ’25 when 20000.0 shares were sold. Officer, DONGFANG LIU completed a deal on May 02 ’25 to buy 20000.0 shares. Meanwhile, PRESIDENT AND CEO Hung David bought 0.3 million shares on Apr 07 ’25.
